NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
Clinical Trials
19 trialsNCT06669572 2026-02-17
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT03752333 2026-01-22
CUPem
Imperial College London
Phase 2 Completed
NCT04795661 2026-01-07
IMHOTEP
Centre Leon Berard
Phase 2 Active not recruiting
NCT04847466 2025-12-24
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05027633 2025-11-19
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT04808999 2025-05-29
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
University of Pittsburgh
Phase 2 Active not recruiting
NCT03391973 2025-04-25
CUP
AHS Cancer Control Alberta
Phase 2 Active not recruiting
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT04739618 2024-07-23
Metastatic Solid Cancer Clinical Trial
ImmunSYS, LLC
Phase 2 Active not recruiting
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT03832673 2021-02-26
PECULIAR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Withdrawn
NCT02883556 2021-01-13
CARSKIN
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed